Contact us : info@bioworlde.com
Home > Product > Antigen-Peptide
CCR7 (R209) Peptide BS2770P
Product NameCCR7 (R209) Peptide
Catalog No.BS2770P
ApplicationsBlocking
Swiss-ProtP32248
Product1 mg/ml in DI water.
Purification&PuritySynthetic peptide CCR7 (R209). (Note: the amino acid sequence is proprietary). The purity is > 98%.
Storage&StabilityStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
SpecificityThis peptide can be used with studies using BS2770 CCR7 (R209) pAb.
Browse similar products>>
Size Price
1mg $368
Add to cart My orders
Product Name :
CCR7 (R209) Peptide
Applications :
Blocking
Background :
C-C chemokine receptor family members include CKR-1, CKR-2A, CKR-2B, CKR-3, CKR-4, CKR-5, CKR-6, CKR-7 and the Duffy blood group antigen. Each of these receptors are G protein-coupled, seven pass transmembrane domain proteins whose major physiological role is to function in the chemotaxis of T cells and phagocytic cells to areas of inflammation. However, this receptor family has also been shown to facilitate viral infection. Termed a “co-receptor”, CKR-5, along with CD4, has been shown to be a major receptor for HIV. CKR-5 tends to associate with macrophagetropic viruses, such as macrophage tropic HIV-1, while CKR-2B and CKR-3 bind a minority of viruses.
Alternative Name :
C-C chemokine receptor type 7; C-C CKR-7; CC-CKR-7; CCR-7; BLR2; CDw197; Epstein-Barr virus-induced G-protein coupled receptor 1; EBI1; EBV-induced G-protein coupled receptor 1; MIP-3 beta receptor; CD197; CKR7 CMKBR7; EBI1; EVI1
Swiss-Prot :
P32248
Product :
1 mg/ml in DI water.
Purification&Purity :
Synthetic peptide CCR7 (R209). (Note: the amino acid sequence is proprietary). The purity is > 98%.
Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :
This peptide can be used with studies using BS2770 CCR7 (R209) pAb.
Blocking peptide available as BS2770PP
COPYRIGHT © 2015-2018 Bioworld Technology, Inc. All rights reserved POLYCLONAL AND MONOCLONAL ANTIBODY CENTER